文献速递慢性肾脏病

慢性肾脏病早期诊断、主动预防与治疗策略的演变

Evolving strategies for early diagnosis, proactive prevention and treatment of CKD.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本文为综述,指出慢性肾脏病(CKD)是全球增长最快的死因之一,预测到2050年将成为西欧和日本第三大死因;21世纪肾保护药物大量涌现,但20世纪仅对糖尿病患者评估白蛋白尿的概念限制了早期诊断与治疗;作者提出推广ABCDE方法早期检测心-肾-代谢风险,并发展pre-CKD概念以指导预防CKD的药物治疗。

要点

  • CKD是全球增长最快的死因之一,预测到2050年将成为西欧和日本第三大死因。
  • 仅对糖尿病患者评估白蛋白尿的旧概念,限制了多达80%最终发生肾衰竭者的早期诊断与治疗。

核心结论

  • 肾脏医学的下一步应是广泛采用ABCDE方法(白蛋白尿、血压、胆固醇、糖尿病和估算肾小球滤过率)进行心-肾-代谢风险的早期检测与治疗,并发展pre-CKD概念以指导预防CKD的药物治疗。

研究设计与样本

  • 综述,聚焦CKD早期诊断、主动预防与治疗策略的演变。

主要发现

  • 心血管疾病死亡率在下降,而CKD是全球增长最快的死因之一,预测到2050年将成为西欧和日本第三大死因。
  • KRT结局欠佳:与一般人群相比,透析女性预期寿命缩短可达44年,有功能肾移植物的女性缩短可达22年。
  • 20世纪仅对糖尿病患者评估白蛋白尿的概念,限制了多达80%最终发生肾衰竭者的早期诊断与治疗。
  • 临床试验提示,当肾小球滤过率正常时基于白蛋白尿诊断CKD并启动肾保护治疗,可能将需要KRT的时间延迟近3年,意味着许多老年受试者将不需要KRT。

临床怎么用

  • 作者认为应广泛采用ABCDE方法(白蛋白尿、血压、胆固醇、糖尿病和估算肾小球滤过率)进行心-肾-代谢风险的早期检测与治疗。
  • 作者认为应发展pre-CKD概念,以指导预防CKD的药物治疗,并在全人群健康生活方式措施基础上实施,而不仅针对高危人群。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) is among the fastest growing global causes of death, forecasted to become the third leading cause of death in Western Europe and Japan by 2050. In contrast, mortality from cardiovascular disease is decreasing. Cardiovascular medicine is focused on identifying people at high risk and intervening to prevent cardiovascular events. The focus of kidney medicine has evolved over time. Last century the focus was on treating kidney failure by kidney replacement therapy (KRT). However, KRT outcomes are suboptimal. Life expectancy is up to 44 (women on dialysis) to 22 years (women with functioning kidney grafts) shorter on KRT than in the general population. The 21st century has witnessed an explosion of highly effective kidney-protective drugs that may both prevent and slow the progression of CKD while addressing the full cardiovascular-kidney-metabolic (CKM) syndrome spectrum, i.e. also improving cardiovascular and metabolic outcomes. However, these advances have met a barrier: 20th century concepts on whom to test for CKD, which focus on assessing albuminuria just in people with diabetes mellitus. This outdated concept limits early diagnosis and treatment in up to 80% of people who eventually develop kidney failure. Clinical trials suggest that starting kidney protective therapy because CKD was diagnosed based on albuminuria, when glomerular filtration rate is normal, may delay the need for KRT for up to nearly 3 decades, meaning that many older subjects would not require KRT. To improve outcomes, the next two steps in kidney medicine should involve the widespread adoption of the ABCDE (albuminuria, blood pressure, cholesterol, diabetes and estimated glomerular filtration rate) approach for early detection and treatment of CKM risk, followed by developing the concept of pre-CKD that may guide pharmacologic interventions targeted to prevent CKD, on top of healthy lifestyle measures for the entire population, not just for those at risk.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ortiz A, Yanagita M, Yokoi H, et al. Evolving strategies for early diagnosis, proactive prevention and treatment of CKD. Nephrol Dial Transplant. 2026. PMID: 40795360. doi:10.1093/ndt/gfaf151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。